Cargando…
Suppression of PC-1/PrLZ sensitizes prostate cancer cells to ionizing radiation by attenuating DNA damage repair and inducing autophagic cell death
Radiotherapy is promising and effective for treating prostate cancer but the addition of a tumor cell radiosensitizer would improve therapeutic outcomes. PC-1/PrLZ, a TPD52 protein family member is frequently upregulated in advanced prostate cancer cells and may be a biomarker of aggressive prostate...
Autores principales: | Shang, Zeng-Fu, Wei, Qiang, Yu, Lan, Huang, Fang, Xiao, Bei-Bei, Wang, Hongtao, Song, Man, Wang, Li, Zhou, Jianguang, Wang, Jian, Li, Shanhu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5308731/ https://www.ncbi.nlm.nih.gov/pubmed/27694690 http://dx.doi.org/10.18632/oncotarget.11470 |
Ejemplares similares
-
PC-1/PrLZ confers resistance to rapamycin in prostate cancer cells through increased 4E-BP1 stability
por: Yu, Lan, et al.
Publicado: (2015) -
PrLZ increases prostate cancer docetaxel resistance by inhibiting LKB1/AMPK-mediated autophagy
por: Zeng, Jin, et al.
Publicado: (2018) -
Loss of miR-449a-caused PrLZ overexpression promotes prostate cancer metastasis
por: Chen, Wei, et al.
Publicado: (2017) -
ERK1/2 inhibits Cullin 3/SPOP-mediated PrLZ ubiquitination and degradation to modulate prostate cancer progression
por: Fan, Yizeng, et al.
Publicado: (2022) -
PC-1 works in conjunction with E3 ligase CHIP to regulate androgen receptor stability and activity
por: Wang, Jian, et al.
Publicado: (2016)